{"disease":{"id":"cervical-cancer-recurrent","name":"cervical cancer recurrent"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07266350","title":"A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for the Treatment of Cervical Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1300,"lead_sponsor_name":"Qi Zhou","has_results":false},{"nct_id":"NCT01040312","title":"An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors","phase":"","overall_status":"COMPLETED","enrollment_count":321,"lead_sponsor_name":"Daiichi Sankyo Co., Ltd.","has_results":false},{"nct_id":"NCT06781151","title":"A Study to Explore Personalized Treatment for Patients With Recurrent Gynecological Malignancies Based on MTB","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07493928","title":"HPV After chemoRadioTherapy","phase":"","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"General University Hospital, Prague","has_results":false},{"nct_id":"NCT07472153","title":"PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"N.N. Alexandrov National Cancer Centre","has_results":false},{"nct_id":"NCT07143292","title":"A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT03170570","title":"the Re-irradiation of Recurrent Cervical Cancer by IMRT","phase":"NA","overall_status":"UNKNOWN","enrollment_count":108,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06238635","title":"Dostarlimab and Cobolimab in Advanced Cervical Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":66,"lead_sponsor_name":"Meghan Shea","has_results":false},{"nct_id":"NCT07141186","title":"QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therapy","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT03602079","title":"Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Klus Pharma Inc.","has_results":false},{"nct_id":"NCT03912402","title":"Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA)","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":49,"lead_sponsor_name":"Biocad","has_results":false},{"nct_id":"NCT06157151","title":"PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":46,"lead_sponsor_name":"Precigen, Inc","has_results":false},{"nct_id":"NCT06455046","title":"Efficacy and Safety of AK104 Combined With Chemotherapy and Recombinant Human Adenovirus 5 Injection in Cervical Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":37,"lead_sponsor_name":"Fujian Cancer Hospital","has_results":false},{"nct_id":"NCT07363330","title":"A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":32,"lead_sponsor_name":"Zhongnan Hospital","has_results":false},{"nct_id":"NCT06644846","title":"Spatially Fractionated Radiation Treatment for Gynaecological Cancers","phase":"NA","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Tata Memorial Hospital","has_results":false},{"nct_id":"NCT03277482","title":"Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":16,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT04230954","title":"Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"University of South Alabama","has_results":false}],"total":17},"guidelines":[],"source":"Drug Landscape verified database"}